We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pittsburgh-based biotech company, Krystal Biotech, recently announced FDA approval of a revolutionary and redosable gene therapy to treat dystrophic epidermolysis bullosa (DEB)